Role of interleukin 16 in multiple myeloma

Journal of the National Cancer Institute

Volumn 104, Issue 13, 2012, Pages 1005-1020

  Atanackovic, Djordje ^a   Hildebrandt, York ^a   Templin, Julia ^a   Cao, Yanran ^a   Keller, Christiane ^a   Panse, Jens ^a   Meyer, Sabrina ^a   Reinhard, Henrike ^a   Bartels, Katrin ^a   Lajmi, Nesrine ^a   Sezer, Orhan ^a   Zander, Axel R ^a   Marx, Andreas H ^a   Uhlig, Ria ^a   Zustin, Jozef ^a   Bokemeyer, Carsten ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APRIL PROTEIN; CD4 ANTIGEN; CD9 ANTIGEN; CYTOKINE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 16 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SMALL INTERFERING RNA; SOMATOMEDIN; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR PROMOTION;

ADULT; AGED; ANTIGENS, CD4; ANTIGENS, CD9; APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; PLASMA CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84863928400     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs257     Document Type: Article

References (71)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
2. Dispenzieri A, Lacy MQ, Greipp PR. Multiple Myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, ed. Wintrobe's Clinical Hematology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:2583-2636.
3. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968-3977.
4. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol. 2006;34(10):1289-1295.
5. Alexandrakis MG, Passam FH, Kyriakou DS, et al. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol. 2004;75(2):101-106.
6. Koike M, Sekigawa I, Okada M, et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res. 2002;26(8):705-711.
7. Bellomo G, Allegra A, Alonci A, et al. Serum levels of interleukin-16 in lymphoid malignancies. Leuk Lymphoma. 2007;48(6):1225-1227.
8. Cruikshank WW, Center DM, Nisar N, et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA. 1994;91(11):5109-5113.
9. Chupp GL, Wright EA, Wu D, et al. Tissue and T cell distribution of precursor and mature IL-16. J Immunol. 1998;161(6):3114-3119.
10. Wu DM, Zhang Y, Parada NA, et al. Processing and release of IL-16 from CD4+ but not CD8+ T cells is activation dependent. J Immunol. 1999;162(3):1287-1293.
11. Lim KG, Wan HC, Bozza PT, et al. Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol. 1996;156(7):2566-2570.
12. Lorentz A, Schwengberg S, Sellge G, et al. Human intestinal mast cells are capable of producing different cytokine profiles: role of IgE receptor cross-linking and IL-4. J Immunol. 2000;164(1):43-48.
13. Rumsaeng V, Cruikshank WW, Foster B, et al. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol. 1997;159(6):2904- 2910.
14. Elssner A, Doseff AI, Duncan M, et al. IL-16 is constitutively present in peripheral blood monocytes and spontaneously released during apoptosis. J Immunol. 2004;172(12):7721-7725.
15. Kaser A, Dunzendorfer S, Offner FA, et al. A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol. 1999;163(6):3232- 3238.
16. Kaser A, Dunzendorfer S, Offner FA, et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol. 2000;165(5):2474-2480.
17. Kramer MF, Mack B, Rasp G. Immunohistological expression of interleukin 16 in human tonsils. Arch Otolaryngol Head Neck Surg. 2001;127(9):1120-1125.
18. Baier M, Bannert N, Werner A, et al. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci USA. 1997;94(10):5273-5277.
19. Sciaky D, Brazer W, Center DM, et al. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol. 2000;164(7):3806-3814.
20. Ludwiczek O, Kaser A, Koch RO, et al. Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. Eur Cytokine Netw. 2001;12(3):478-486.
21. Zhang Y, Center DM, Wu DM, et al. Processing and activation of prointerleukin-16 by caspase-3. J Biol Chem. 1998;273(2):1144-1149.
22. Gianoukakis AG, Martino LJ, Horst N, et al. Cytokine-induced lymphocyte chemoattraction from cultured human thyrocytes: evidence for interleukin-16 and regulated upon activation, normal T cell expressed, and secreted expression. Endocrinology. 2003;144(7):2856-2864.
23. Cruikshank WW, Berman JS, Theodore AC, et al. Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol. 1987;138(11):3817-3823.
24. Qi JC, Wang J, Mandadi S, et al. Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood. 2006;107(1):135-142.
25. Laberge S, Ghaffar O, Boguniewicz M, et al. Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol. 1998;102(4 pt 1):645-650.
26. Stoitzner P, Ratzinger G, Koch F, et al. Interleukin-16 supports the migration of Langerhans cells, partly in a CD4-independent way. J Invest Dermatol. 2001;116(5):641-649.
27. Rand TH, Cruikshank WW, Center DM, et al. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med. 1991;173(6):1521-1528.
28. Matsumoto Y, Fujita T, Hirai I, et al. Immunosuppressive effect on T cell activation by interleukin-16-and interleukin-10-cDNA-double-transfected human squamous cell line. Burns. 2009;35(3):383-389.
29. Klimiuk PA, Goronzy JJ, Weyand CM. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol. 1999;162(7):4293-4299.
30. Newell MK, Haughn LJ, Maroun CR, et al. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature. 1990;347(6290):286-289.
31. Theodore AC, Center DM, Nicoll J, et al. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol. 1996;157(5):1958-1964.
32. Cruikshank WW, Lim K, Theodore AC, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol. 1996;157(12):5240-5248.
33. Ogasawara H, Takeda-Hirokawa N, Sekigawa I, et al. Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells. Immunology. 1999;96(2):215-219.
34. Parada NA, Center DM, Kornfeld H, et al. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol. 1998;160(5):2115-2120.
35. McFadden C, Morgan R, Rahangdale S, et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol. 2007;179(10):6439-6445.
36. Atanackovic D, Luetkens T, Hildebrandt Y, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009;15(4):1343-1352.
37. Berens HM, Tyler KL. The proapoptotic Bcl-2 protein Bax plays an important role in the pathogenesis of reovirus encephalitis. J Virol. 2011;85(8):3858-3871.
38. Cao Y, Gordic M, Kobold S, et al. An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. J Immunol Methods. 2010;358(1-2):56-65.
39. Yoshimoto T, Wang CR, Yoneto T, et al. Role of IL-16 in delayed-type hypersensitivity reaction. Blood. 2000;95(9):2869-2874.
40. Zhang XG, Bataille R, Jourdan M, et al. Granulocyte-macrophage colonystimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood. 1990;76(12):2599-2605.
41. Till KJ, Burthem J, Lopez A, et al. Granulocyte-macrophage colony-stimulating factor receptor: stage-specific expression and function on late B cells. Blood. 1996;88(2):479-486.
42. Villunger A, Egle A, Kos M, et al. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity. Br J Haematol. 1998;102(4):1069-1080.
43. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112(2):286-297.
44. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148-3157.
45. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66(13):6675-6682.
46. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747-1756.
47. Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385-5392.
48. Xie S, Li J, Wang JH, et al. IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J Immunol. 2010;184(5):2289-2296.
49. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190-197.
50. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332-2336.
51. Richmond J, Tuzova M, Parks A, et al. Interleukin-16 as a marker of Sezary syndrome onset and stage. J Clin Immunol. 2011;31(1):39-50.
52. Sharma V, Sparks JL, Vail JD. Human B-cell lines constitutively express and secrete interleukin-16. Immunology. 2000;99(2):266-271.
53. Liebrich M, Guo LH, Schluesener HJ, et al. Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz). 2007;55(1):41-47.
54. Gao LB, Rao L, Wang YY, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2009;30(2):295-299.
55. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genomewide association study of prostate cancer. Nat Genet. 2008;40(3):310-315.
56. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother. 2001;55(2):111-116.
57. Qin XJ, Shi HZ, Huang ZX, et al. Interleukin-16 in tuberculous and malignant pleural effusions. Eur Respir J. 2005;25(4):605-611.
58. Szabo P, Zhao K, Kirman I, et al. Maturation of B cell precursors is impaired in thymic-deprived nude and old mice. J Immunol. 1998;161(5):2248-2253.
59. Trudelle A, El Bassam S, Pinsonneault S, et al. Interleukin-16 inhibits immunoglobulin e production by B lymphocytes. Int Arch Allergy Immunol. 2007;143(2):109-118.
60. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868.
61. Vesely PW, Staber PB, Hoefler G, et al. Translational regulation mechanisms of AP-1 proteins. Mutat Res. 2009;682(1):7-12.
62. Zhang Y, Kornfeld H, Cruikshank WW, et al. Nuclear translocation of the N-terminal prodomain of interleukin-16. J Biol Chem. 2001;276(2):1299-1303.
63. Wilson KC, Cattel DJ, Wan Z, et al. Regulation of nuclear Prointerleukin-16 and p27(Kip1) in primary human T lymphocytes. Cell Immunol. 2005;237(1):17-27.
64. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26(17):2895-2900.
65. Ryan TC, Cruikshank WW, Kornfeld H, et al. The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. J Biol Chem. 1995;270(29):17081-17086.
66. Bandeira-Melo C, Sugiyama K, Woods LJ, et al. IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4-and autocrine CCR3-chemokine-mediated signaling. J Immunol. 2002;168(9):4756-4763.
67. Cruikshank WW, Greenstein JL, Theodore AC, et al. Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J Immunol. 1991;146(9):2928-2934.
68. Mathy NL, Bannert N, Norley SG, et al. Cutting edge: CD4 is not required for the functional activity of IL-16. J Immunol. 2000;164(9):4429-4432.
69. Shallal S, Kornbluth J. CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood. 2000;96(1):224-233.
70. De Bruyne E, Andersen TL, De Raeve H, et al. Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia. 2006;20(10):1870-1879.
71. De Bruyne E, Bos TJ, Asosingh K, et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res. 2008;14(10):2918-2926.